Dudediligence.

Denali Therapeutics Inc

DNLINASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$3.6MJun ’26
Net income, by quarter
−$107.2MSep ’24−$114.8MDec ’24−$133.0MMar ’25−$124.1MJun ’25−$126.9MSep ’25−$128.5MDec ’25−$128.4MMar ’26−$127.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$48.7M$105.1M$330.5M$0.00$0.00
Operating income−$295.8M−$340.7M−$196.7M−$487.3M−$555.3M
Net income−$290.6M−$326.0M−$145.2M−$422.8M−$512.5M
Operating cash flow−$211.4M−$244.7M−$358.0M−$347.7M−$412.6M
Free cash flow−$219.9M−$262.5M−$370.9M−$363.6M−$422.1M
Cash$293.5M$218.0M$127.1M$175.0M$205.3M
Shares outstanding122.3M136.0M138.4M144.2M156.2M